Expression of inflammatory cytokines by adipose tissue from patients with endometrial cancer

Obesity results in increased mortality from many forms of cancer. We looked at the levels of gene expression for TNF alpha, IL-6, I kappa B kinase (inhibitor of NF-kappa B), CD 68 (glycoprotein expressed on macrophages) and leptin in samples of adipose tissue from individuals with endometrial cancer versus patients with benign conditions. This is a prospective study which included patients of a gynecologic oncology group. A piece of omental tissue was harvested from them during surgery. RNA was purified from all samples. Relative amounts of RNA for I kappa B, TNF alpha, IL-6, CD68 and leptin were calculated. Pearson's correlation method was used to correlate RNA levels with BMI. Logistic regression method was used to compare gene expression for cancer and control groups. The total sample size was 56 (24 endometrial cancer and 32 controls). I kappa B, TNF alpha and IL-6 levels increased linearly with increasing BMI in the control group. There was no correlation of I kappa B, TNF alpha, IL-6 or CD-68 levels with cancer status of the patients. Leptin had a weak protective effect against endometrial cancer (odds ratio = 0.92). Obesity is associated with increased expression of certain inflammatory cytokines in the adipose tissue. However, increased levels of these inflammatory markers in the adipose tissue of the omentum are not associated with presence of endometrial cancer.

Endometrial cancer; Inflammation; Cytokines; Obesity

[1] Defining Overweight and Obesity. vol 2004: Centers for Disease Control, 2003. www.cdc.gov/nccdphp/dnpa/obesity/defining.htm:

[2] Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J.: “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults”. N. Engl. J. Med., 2003, 348, 1625.

[3] Hotamisligil G.S., Arner P, Caro J.F., Atkinson R.L., Spiegelman B.M.: “Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance”. J. Clin. Invest., 1995, 95, 2409.

[4] Purohit A., Ghilchik M.W., Duncan L., Wang D.Y., Singh A., Walker M., Reed M.J.: “Aromatase activity and interleukin-6 production by normal and malignant breast tissues”. J. Clin. Endocrinol. Metab., 1995, 80, 3052.

[5] Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Jr.: “Obesity is associated with macrophage accumulation in adipose tissue”. J. Clin. Invest., 2003, 112, 1796.

[6] Xu H., Barnes G.T., Yang Q., Tang G., Yang D., Chou C.J. et al.: “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance”. J. Clin. Invest., 2003, 112, 1821.

[7] Charriere G., Cousin B., Arnaud E., André M., Bacou F., Penicaud L., Penicaud L., Casteilla L.: “Preadipocyte conversion to macrophage. Evidence of plasticity”. J. Biol. Chem., 2003, 278, 9850.

[8] Aggarwal B.B.: “Nuclear factor-kappaB: the enemy within”. Cancer Cell., 2004, 6, 203.

[9] Gilmore T.D., Kalaitzidis D., Liang M.C., Starczynowski D.T.: “The c-Rel transcription factor and B-cell proliferation: A deal with the devil”. Oncogene, 2004, 23, 2275.

[10] Bond M., Fabunmi R.P., Baker A.H., Newby A.C.: “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB”. FEBS Lett., 1998, 435, 29.

[11] Sharma A., Bartell S.M., Baile C.A., Chen B., Podolsky R.H., McIndoe R.A., She J.X.: “Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice”. PLoS One, 2010, 5, e12147.

[12] Aoki N., Yokoyama R., Asai N., Ohki M., Ohki Y., Kusubata K. et al.: “Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis in vivo and in vitro”. Endocrinology, 2010, 151, 2567.

[13] Vona-Davis L., Rose D.P.: “Angiogenesis, adipokines and breast cancer”. Cytokine Growth Factor Rev., 2009, 20, 193.

[14] Kaaks R., Lukanova A., Kurzer M.S.: “Obesity, endogenous hormones and endometrial cancer risk. A synthetic review”. Cancer Epidemiol. Biomark. Prevent., 2002, 12, 1531.

[15] Rice L.W.: “Hormone prevention strategies for breast, endometrial and ovarian cancers”. Gynecol. Oncol., 2010, 118, 202.

[16] Wellen K.E., Hotamisligil G.S.: “Obesity-induced inflammatory changes in adipose tissue”. J. Clin. Invest., 2003, 112, 1785.

[17] Drabkin H.A., Gemmill R.M.: “Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC)”. Adv. Cancer Res., 2010, 107, 39.

[18] Ribeiro A.M., Andrade S., Pinho F., Monteiro J.D., Costa M., Lopes C. et al.: “Prostate cancer cell proliferation and angiogenesis in different obese mice models”. Int. J. Exp. Pathol., 2010, 91, 374.

[19] Gao J., Tian J., Lv Y., Shi F., Kong F., Shi H., Zhao L.: “Leptin induces functional activation of cyclooxygenase-2 through

JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells”. Cancer Sci., 2009, 100, 389.

[20] Macciò A., Madeddu C., Gramignano G., Mulas C., Floris C., Massa D. et al.: “Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications”. J. Mol. Med., 2010, 88, 677.

[21] Ashizawa N., Yahata T., Quan J., Adachi S., Yoshihara K., Tanaka K.: “Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects”. Gynecol. Oncol., 2010, 119, 65.

[22] Fusco R., Galgani M., Procaccini C., Franco R., Pirozzi G., Fucci L. et al.: “Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting”. Endocr. Relat. Cancer, 2010, 17, 373.